The increase in this receptor occurs after the administration of prothrombin kringle-2 (pKr-2) in rat and mouse brains, which indicates pKr-2 as a new potential TLR4-linked therapeutic target for PD (Shin et al., 2015). This evidence concerns the gene TLR4 and Parkinson disease.